

FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen

June 27, 2019

ATTORNEYS

Landmon, Chad

Chad Landmon

Bloomberg BNA Insights

PRACTICE AREAS

FDA

Bloomberg BNA Insights published the article, "FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen," co-authored by Axinn partner Chad Landmon.

Click [here](#) to access the article.